非黑色素瘤皮肤癌的最新情况。
An update on nonmelanoma skin cancer.
作者信息
Patel Rita V, Frankel Amylynne, Goldenberg Gary
机构信息
Department of Dermatology, Mount Sinai School of Medicine, New York, New York.
出版信息
J Clin Aesthet Dermatol. 2011 Feb;4(2):20-7.
Abstract
Estimates from the American Cancer Society suggest that there are more than two million cases of nonmelanoma skin cancer in the United States per year. The following review highlights the topics of actinic keratoses, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, and Merkel cell carcinoma. This update on the cutting-edge clinical and dermpathologic research will assist the dermatologist in approaching, diagnosing, and managing nonmelanoma skin carcinoma. Immunologic and genetic research into nonmelanoma skin carcinoma has paved the way for novel therapeutic options for patients who were previously without any viable treatment alternatives. While still in preliminary stages, agents, such as ingenol mebutate, vismodegib, and sirolumus, may become integral drugs in the armamentarium of managing cutaneous carcinoma.
摘要
美国癌症协会的估计表明，美国每年有超过两百万例非黑色素瘤皮肤癌病例。以下综述重点介绍光化性角化病、基底细胞癌、鳞状细胞癌、卡波西肉瘤和默克尔细胞癌等主题。这一关于前沿临床和皮肤病理学研究的更新将有助于皮肤科医生对非黑色素瘤皮肤癌进行评估、诊断和管理。对非黑色素瘤皮肤癌的免疫和基因研究为以前没有任何可行治疗选择的患者开辟了新的治疗途径。虽然仍处于初步阶段，但诸如 ingenol mebutate、vismodegib 和西罗莫司等药物可能会成为治疗皮肤癌的重要药物。
相似文献
1
An update on nonmelanoma skin cancer.非黑色素瘤皮肤癌的最新情况。
J Clin Aesthet Dermatol. 2011 Feb;4(2):20-7.
2
Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.探索鬼臼毒素酯预防非黑色素瘤皮肤癌的用途。
Dan Med J. 2017 Nov;64(11).
3
Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.英诺皮肤活化剂：光化性角化病和非黑素瘤皮肤癌的有前途的治疗方法。
J Cutan Med Surg. 2013 May-Jun;17(3):173-9. doi: 10.2310/7750.2012.12050.
4
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.塞来昔布预防非黑素瘤皮肤癌的随机、双盲、安慰剂对照试验。
J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.
5
The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida.南佛罗里达州非黑色素瘤皮肤癌和光化性角化病的发病率。
J Clin Aesthet Dermatol. 2012 Apr;5(4):20-4.
6
New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.光化性角化病治疗的新进展：聚焦于 ingenol 咪喹莫特凝胶。
Clin Cosmet Investig Dermatol. 2012;5:111-22. doi: 10.2147/CCID.S28905. Epub 2012 Aug 24.
7
Ingenol mebutate gel for actinic keratosis.咪喹莫特乳膏治疗光化性角化病。
N Engl J Med. 2012 Mar 15;366(11):1010-9. doi: 10.1056/NEJMoa1111170.
8
Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.光化性角化病的治疗是非黑素瘤皮肤癌预防策略的关键组成部分。
J Clin Aesthet Dermatol. 2010 Jun;3(6):39-44.
9
Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic Keratosis.ingenol mebutate外用凝胶：光化性角化病以外临床应用的现状报告
J Clin Aesthet Dermatol. 2016 Nov;9(11 Suppl 1):S3-S11.
10
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.一项烟酰胺用于皮肤癌化学预防的 3 期随机试验。
N Engl J Med. 2015 Oct 22;373(17):1618-26. doi: 10.1056/NEJMoa1506197.
引用本文的文献
1
Bicubic regression analysis a novel approach for estimation of physicochemical properties of skin cancer drugs through degree based entropy.双三次回归分析：一种基于度熵估计皮肤癌药物物理化学性质的新方法。
Heliyon. 2024 Oct 10;10(20):e39084. doi: 10.1016/j.heliyon.2024.e39084. eCollection 2024 Oct 30.
2
Fundamental Aspects of Skin Cancer Drugs via Degree-Based Chemical Bonding Topological Descriptors.基于键级化学连接拓扑指标的皮肤癌药物基础研究
Molecules. 2023 Apr 24;28(9):3684. doi: 10.3390/molecules28093684.
3
Autophagy Regulation and Photodynamic Therapy: Insights to Improve Outcomes of Cancer Treatment.自噬调节与光动力疗法：改善癌症治疗效果的见解
Front Oncol. 2021 Jan 20;10:610472. doi: 10.3389/fonc.2020.610472. eCollection 2020.
4
Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma.针对皮肤鳞状细胞癌起源细胞的靶向治疗。
Int J Mol Sci. 2019 May 5;20(9):2201. doi: 10.3390/ijms20092201.
5
Immunohistochemical Analysis of Cyclooxygenase-2 in Non-Melanocytic Skin Cancer: Correlation With Morphological Subtype and Histologic Grade.非黑素细胞性皮肤癌中环氧化酶-2的免疫组织化学分析：与形态学亚型和组织学分级的相关性
World J Oncol. 2014 Dec;5(5-6):189-195. doi: 10.14740/wjon869w. Epub 2014 Dec 3.
6
Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer.光动力疗法联合治疗非黑色素瘤皮肤癌
Int J Mol Sci. 2015 Oct 28;16(10):25912-33. doi: 10.3390/ijms161025912.
7
Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.伴有融合抑制因子（SUFU）突变的默克尔细胞癌：病例报告及潜在治疗意义
Dermatol Ther (Heidelb). 2015 Jun;5(2):129-43. doi: 10.1007/s13555-015-0074-5. Epub 2015 Apr 15.
8
Different Anatomical Distribution of Basal Cell Carcinoma Subtypes in Iranian Population: Association between Site and Subtype.伊朗人群中基底细胞癌亚型的不同解剖分布：部位与亚型之间的关联
Ann Dermatol. 2014 Oct;26(5):559-63. doi: 10.5021/ad.2014.26.5.559. Epub 2014 Sep 26.
9
No chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancer: evidence from meta-analysis.非甾体抗炎药对非黑色素瘤皮肤癌无化学预防作用：来自荟萃分析的证据。
PLoS One. 2014 May 14;9(5):e96887. doi: 10.1371/journal.pone.0096887. eCollection 2014.
10
Characteristics of Mixed Type Basal Cell Carcinoma in Comparison to Other BCC Subtypes.混合型基底细胞癌与其他基底细胞癌亚型的特征比较。
Indian J Dermatol. 2014 Jan;59(1):56-9. doi: 10.4103/0019-5154.123496.
本文引用的文献
1
Review ofactinic keratosis. Part I: etiology, epidemiology and clinical presentation.光化性角化病综述。第一部分：病因、流行病学及临床表现。
J Drugs Dermatol. 2010 Sep;9(9):1125-32.
2
Basal cell carcinoma: what's new under the sun.基底细胞癌：太阳下的新事物。
Photochem Photobiol. 2010 May-Jun;86(3):481-91. doi: 10.1111/j.1751-1097.2010.00735.x.
3
PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.PEP005（ ingenol mebutate）凝胶治疗浅表基底细胞癌的局部治疗：一项随机 IIa 期试验的结果。
Australas J Dermatol. 2010 May;51(2):99-105. doi: 10.1111/j.1440-0960.2010.00626.x.
4
Interventions for non-metastatic squamous cell carcinoma of the skin.皮肤非转移性鳞状细胞癌的干预措施。
Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD007869. doi: 10.1002/14651858.CD007869.pub2.
5
Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression.正常人皮肤、光化性角化病和鳞状细胞癌的基因表达模式：疾病进展的一个谱系
Arch Dermatol. 2010 Mar;146(3):288-93. doi: 10.1001/archdermatol.2009.378.
6
Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses.一项随机、双盲、安慰剂对照研究，旨在评估外用1%烟酰胺对光化性角化病的疗效。
Br J Dermatol. 2010 May;162(5):1138-9. doi: 10.1111/j.1365-2133.2010.09659.x. Epub 2010 Mar 1.
7
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.咪喹莫特 2.5% 和 3.75% 乳膏用于治疗光化性角化病：两项为期 2 周、每日应用于面部和脱发头皮的安慰剂对照研究的结果。
J Am Acad Dermatol. 2010 Apr;62(4):582-90. doi: 10.1016/j.jaad.2009.07.004. Epub 2010 Feb 4.
8
Inflammatory monocytes are a reservoir for Merkel cell polyomavirus.炎症单核细胞是 Merkel 细胞多瘤病毒的储存库。
J Invest Dermatol. 2010 Apr;130(4):1146-51. doi: 10.1038/jid.2009.392. Epub 2009 Dec 17.
9
Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score.吡罗昔康 1%凝胶治疗光化性角化病的局部治疗：利用新的临床评分进行的初步开放性研究。
Am J Clin Dermatol. 2010;11(1):45-50. doi: 10.2165/11311170-000000000-00000.
10
Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi's sarcoma.默克尔细胞癌和卡波西肉瘤中默克尔细胞多瘤病毒的检测。
J Med Virol. 2009 Nov;81(11):1951-8. doi: 10.1002/jmv.21608.
Zotero 插件